bioskills offers strategic advice for entrepreneurs and investors bioskills translates excellent science into a real business with an attractive investment case for scientists, entrepreneurs and investors
Jim’s most recent position was CEO of Karolinska Development, a publicly listed Nordic life science investment fund. He joined the company in 2015 to execute a strategic turnaround and reposition the company to become a leading Nordic life science investment company.
Jim founded his own company bioskills in 2013 offering an entrepreneurial approach towards fundraising and strategic advice for entrepreneurs and investors.
Dr. Jim Van heusden worked as a Partner at Gimv from 2001 – 2013 focusing on investments in Life Sciences.
Former investments and BoD representation: Ablynx, ActoGeniX (acquired by Intrexon), Ambit Biosciences (acquired by Daiichi Sankyo), Antisoma, ChemoCentryx, CropDesign (acquired by BASF), Fovea Pharmaceuticals (acquired by Sanofi-Aventis), Hypnion (acquired by Eli Lilly), Movetis (acquired by Shire), Memory Pharmaceuticals (acquired by Hoffmann-La Roche), Multiplicom (acquired by Agilent Technologies), Nereus Pharmaceuticals (acquired by Triphase), Plexxikon (acquired by Daiichi Sankyo), Pronota (acquired by MyCartis), Prosensa (acquired by BioMarin) and Santhera Pharmaceuticals.
Prior to joining Gimv in 2001, he was working as a senior scientist at the department of Oncology Drug Discovery at Janssen Pharmaceutica, a Johnson & Johnson company, where he also served on the research management committee of the collaboration with Rigel Pharmaceuticals.
He holds BSc and MSc degrees in chemistry and biochemistry from the University of Antwerp and a PhD in molecular and cellular biology from the University of Maastricht.